



ANDA 79-153

Torrent Pharma Inc.  
Attention: Dawn M. Chitty  
Director, Regulatory Affairs  
U.S. Agent for: Torrent Pharmaceuticals Limited  
5380 Holiday Terrace, Suite 40  
Kalamazoo, MI 49009

Dear Madam:

This is in reference to your abbreviated new drug application (ANDA) dated July 23, 2007, submitted pursuant to section 505(j) of the Federal Food, Drug, and Cosmetic Act (the Act), for Topiramate Tablets, 25 mg, 50 mg, 100 mg and 200 mg.

Reference is also made to your amendments dated February 5, August 1, and November 5, 2008; and February 3, and February 25, 2009.

We have completed the review of this ANDA and have concluded that adequate information has been presented to demonstrate that the drug is safe and effective for use as recommended in the submitted labeling. Accordingly the ANDA is approved, effective on the date of this letter. The Division of Bioequivalence has determined your Topiramate Tablets, 25 mg, 50 mg, 100 mg and 200 mg, to be bioequivalent and, therefore, therapeutically equivalent to the reference listed drug, Topamax Tablets, 25 mg, 50 mg, 100 mg and 200 mg, respectively, of Ortho McNeil Janssen Pharmaceuticals, Inc. Your dissolution testing should be incorporated into the stability and quality control program using the same method proposed in your application.

The reference listed drug (RLD) upon which you have based your ANDA, Topamax Tablets of Ortho McNeil Janssen Pharmaceuticals Inc., is subject to periods of patent protection. The following patents and expiration dates are currently listed in the agency's publication titled Approved Drug Products with Therapeutic Equivalence Evaluations (the "Orange Book") for this drug product:

<u>U.S. Patent Number</u>	<u>Expiration Date</u>
5,998,380 (the '380 patent)	April 13, 2016
6,503,884 (the '884 patent)	April 13, 2016
7,018,983 (the '983 patent)	April 13, 2016
7,498,311 (the '311 patent)	April 13, 2016

With respect to each of these patents, your ANDA contains statements under section 505(j)(2)(A)(viii) of the Act that that these are method of use patents, and that these patents are not infringed by any indication for which you are seeking approval under this ANDA.

Under section 506A of the Act, certain changes in the conditions described in this ANDA require an approved supplemental application before the change may be made.

We note that if FDA requires a Risk Evaluation & Mitigation Strategy (REMS) for a listed drug, an ANDA citing that listed drug also will be required to have a REMS, See 505-1(i).

Postmarketing reporting requirements for this ANDA are set forth in 21 CFR 314.80-81 and 314.98. The Office of Generic Drugs should be advised of any change in the marketing status of this drug.

Promotional materials may be submitted to FDA for comment prior to publication or dissemination. Please note that these submissions are voluntary. If you desire comments on proposed launch promotional materials with respect to compliance with applicable regulatory requirements, we recommend you submit, in draft or mock-up form, two copies of both the promotional materials and package insert directly to:

Food and Drug Administration  
Center for Drug Evaluation and Research  
Division of Drug Marketing, Advertising, and Communications  
5901-B Ammendale Road  
Beltsville, MD 20705

We call your attention to 21 CFR 314.81(b)(3) which requires that all promotional materials be submitted to the Division of Drug Marketing, Advertising, and Communications with a completed Form FDA 2253 at the time of their initial use.

Within 14 days of the date of this letter, submit updated content of labeling [21 CFR 314.50(1)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/oc/datacouncil/spl.html>, that is identical in content to the approved labeling. Upon receipt and verification, we will transmit that version to the National Library of Medicine for public dissemination. For administrative purposes, please designate this submission as "**Miscellaneous Correspondence - SPL for Approved ANDA 79-153**".

Sincerely yours,

*{See appended electronic signature page}*

Gary Buehler  
Director  
Office of Generic Drugs  
Center for Drug Evaluation and Research

-----  
**This is a representation of an electronic record that was signed electronically and  
this page is the manifestation of the electronic signature.**  
-----

/s/

-----  
Robert L. West  
3/27/2009 12:58:48 PM  
Deputy Director, for Gary Buehler